Why is Neuland Laboratories Ltd falling/rising?

Recent Price Performance and Market Comparison

Neuland Laboratories has underperformed both its sector and the broader market in recent weeks. Over the past week, the stock declined by 2.99%, contrasting with the Sensex’s modest gain of 0.23%. The one-month performance further highlights this divergence, with the stock falling 6.82% while the benchmark rose 0.77%. Year-to-date, the stock has dropped 16.70%, significantly underperforming the Sensex’s 2.82% decline. Despite these short-term setbacks, the stock has delivered a robust 11.00% return over the last year, outpacing the Sensex’s 9.35% gain. However, this positive annual return masks underlying challenges that have emerged more recently.

On the trading day of 20-Feb, the stock’s intraday low reached ₹12,557, representing a 3.63% drop from the previous close. The weighted average price indicates that a greater volume of shares traded closer to this lower price point, signalling selling pressure. Additionally, Neuland Laboratories is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically suggests a bearish trend in technical analysis.

Investor Participation and Liquidity

Interestingly, investor participation has increased recently, with delivery volume on 19 Feb rising by 30.06% compared to the five-day average, reaching 15,080 shares. This heightened activity suggests that while the stock is falling, there is still significant trading interest. The stock’s liquidity remains adequate for sizeable trades, with a trade size capacity of approximately ₹1.23 crore based on 2% of the five-day average traded value.

Fundamental Strengths and Institutional Backing

Neuland Laboratories maintains a low average debt-to-equity ratio of 0.10 times, indicating a conservative capital structure with limited leverage risk. Institutional investors hold a substantial 35.61% stake in the company, and their holdings have increased by 1.06% over the previous quarter. This level of institutional confidence often reflects a belief in the company’s long-term prospects, given their superior analytical resources compared to retail investors.

Challenges in Growth and Profitability

Despite these positives, the company faces significant headwinds in its operational performance. Over the past five years, net sales have grown at a modest annual rate of 12.25%, while operating profit has expanded at 15.28% annually. These growth rates are relatively subdued for a pharmaceutical company expected to deliver robust expansion. More concerning is the recent quarterly profit before tax (excluding other income), which has declined by 21.7% to ₹46.43 crore compared to the average of the previous four quarters.

The company’s return on capital employed (ROCE) stands at a low 14.48%, and its inventory turnover ratio is also at a five-year low of 2.80 times, signalling inefficiencies in asset utilisation and inventory management. These factors contribute to a less favourable operational outlook.

Valuation Concerns and Market Sentiment

Neuland Laboratories is currently trading at a premium valuation, with a price-to-book value ratio of 10.1, which is high relative to its peers and historical averages. This elevated valuation is difficult to justify given the company’s declining profitability and operational challenges. The return on equity (ROE) of 12.1% is modest and does not fully support the stock’s expensive price level. Furthermore, despite the stock’s 11.00% return over the past year, the company’s profits have fallen by 25.4% during the same period, indicating a disconnect between market price and underlying earnings performance.

These factors have contributed to a negative sentiment among investors, reflected in the stock’s three consecutive days of decline and a cumulative loss of 7.51% over this period. The underperformance relative to the sector by 3.07% today further emphasises the cautious stance investors are adopting.

Conclusion

In summary, Neuland Laboratories Ltd’s recent share price decline is primarily driven by concerns over weakening profitability, subdued growth prospects, and stretched valuation metrics. While institutional investors maintain a significant stake and the company benefits from low leverage, these positives have not been sufficient to offset the negative impact of falling profits and operational inefficiencies. The stock’s technical indicators and recent trading patterns reinforce the bearish momentum, suggesting that investors remain wary amid these challenges.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →